Document is current
Any future updates will be listed below
-
Authors
Yoshimura, Takuji https://orcid.org/0000-0002-7856-0679
Furukawa, Shoko
Oda, Akihisa
Matsumoto, Tomoko
Sasai, Kana
Shima, Midori
Nogami, Keiji
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (Grant No. 18K07885, 21K07804)
Sanofi (Collaborative Research Agreement)
- License Information
-
More Information
Article History
Received: 9 February 2022
Revised: 14 April 2022
Accepted: 14 April 2022
First Online: 3 May 2022
Declarations
:
: TY and AO received funding from Bioverativ Inc./Sanofi S.A, SF received funding from Bioverativ Inc./Sanofi S.A; and taught a course endowed by CSL Behring; and received personal payment for presentation from Chugai Pharmaceutical Co., Ltd. and Shire Plc /Takeda Co., TM and KS have no conflict of interest, MS received funding from Chugai Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd., Shire Plc /Takeda Co., Bioverativ Inc./Sanofi S.A., CSL Behring, KM Biologics Co., Novo Nordisk A/S; and payment for lectures on speaker’s bureau from Chugai, Bioverativ Inc/Sanofi S.A, Bayer; and is a member of the board of directors/ advisory committee member for Chugai Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd., Bayer AG, Bioverativ Inc./Sanofi S.A., KN received research funding from Chugai Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd., Shire Plc, Takeda Pharmaceutical Co., Bioverativ Inc./Sanofi S.A., Novo Nordisk A/S, Bayer AG, KM Biologics Co., Sysmex Co.; and consulting fee from Chugai Pharmaceutical Co., Ltd.; and payment for lectures on speaker’s bureau from Chugai Pharmaceutical Co., Ltd., Shire Plc,/Takeda Co, Bioverativ Inc./Sanofi S.A., Novo Nordisk A/S, Bayer AG, KM Biologics Co., and Sysmex corporation; and is listed as a member of the board of directors or advisory committee member for Chugai Pharmaceutical Co., Ltd. and F. Hoffmann-La Roche Ltd.
